MedDataX Logo

Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts

NCT ID: NCT07307131

Last Updated: 2025-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-01

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study compares the effectiveness and safety of two different intralesional treatments for cutaneous warts: a combination of furosemide and digoxin versus polidocanol.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, single-blind, comparative clinical study to evaluate the efficacy and safety of intralesional combined furosemide-digoxin versus intralesional polidocanol in the treatment of cutaneous warts. Sixty-four adult patients were randomized to receive one of the two treatments every two weeks for a maximum of four sessions. The main goal was to see which treatment was better at completely clearing the warts. The study also looked at side effects and how often the warts came back within six months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cutaneous Warts, Human Papillomavirus (HPV)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Cutaneous warts, human papillomavirus, intralesional therapy, furosemide, digoxin, polidocanol, sclerotherapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Single (Participant)

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group A

Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Group Type EXPERIMENTAL

Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Intervention Type DRUG

Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Group B

Intralesional Polidocanol 2%

Group Type ACTIVE_COMPARATOR

Intralesional polidocanol 2%

Intervention Type DRUG

Group B (Active Comparator): Intralesional polidocanol 2%

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Group A (Experimental): Intralesional combined furosemide (10 mg/ml) and digoxin (0.25 mg/ml)

Intervention Type DRUG

Intralesional polidocanol 2%

Group B (Active Comparator): Intralesional polidocanol 2%

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients over 18 years of age with single or multiple cutaneous warts.

Exclusion Criteria

* History of allergies to the study medications, known cardiac or renal disease, hypertension, pregnancy or lactation, and any signs of systemic or local infection.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Benha University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ghada Mohamed Shams

dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ghada Shams, MD

Role: PRINCIPAL_INVESTIGATOR

Benha University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

faculty of Medicine

Banhā, Qalyubia Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

intralesional treatment warts

Identifier Type: -

Identifier Source: org_study_id